- Raw materials
- Antibacterials
- Pirlimycin
Pirlimycin API Manufacturers & Suppliers
0 verified results
All Pirlimycin data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Pirlimycin | CAS No: 79548-73-5 | GMP-certified suppliers
A medication that treats bovine mastitis by targeting gram-positive bacterial infections to support dairy cattle health and ensure effective veterinary antimicrobial therapy.
Therapeutic categories
Product Snapshot
- Pirlimycin is an injectable small molecule antibiotic formulation
- It is primarily used for veterinary applications targeting bacterial infections
- The product is approved for veterinary use, with regulatory clearance in key animal health markets
Clinical Overview
The pharmacological action of pirlimycin involves inhibition of bacterial protein synthesis through binding to the 50S ribosomal subunit. This impedes peptide chain elongation, thereby exhibiting bacteriostatic activity against susceptible gram-positive organisms commonly implicated in mastitis. Despite its established utility in veterinary contexts, detailed pharmacodynamic parameters and human clinical indications are not specified.
Regarding absorption, distribution, metabolism, and excretion (ADME), pirlimycin is administered intramammarily, facilitating high local concentrations at the site of infection with limited systemic exposure. Its absorption from the mammary gland is minimal, reducing systemic toxicity risk in treated animals. Metabolic pathways and elimination half-life data remain limited in publicly available literature but are consistent with other lincosamides metabolized hepatically and excreted renally or via bile.
Safety and toxicity considerations for pirlimycin focus on its use in food-producing animals, necessitating adherence to established withdrawal periods to avoid antimicrobial residues in milk. The drug's neurotoxic categorization warns of potential adverse effects at high systemic concentrations, although such occurrences are rare with proper administration. Monitoring for hypersensitivity reactions is advised, given the structural similarity to other lincosamide antibiotics.
API sourcing for pirlimycin should emphasize pharmaceutical-grade purity, compliance with veterinary pharmacopeia standards, and consideration of regulatory approvals specific to veterinary use. Consistent quality control is critical to maintain efficacy and safety profiles in dairy production settings, where contamination or substandard materials could impact both animal health and food safety.
Identification & chemistry
| Generic name | Pirlimycin |
|---|---|
| Molecule type | Small molecule |
| CAS | 79548-73-5 |
| UNII | LM19JT6G5K |
| DrugBank ID | DB11537 |
Formulation & handling
- Pirlimycin is a small molecule antibiotic with moderate water solubility suitable for oral or veterinary formulations.
- Its low LogP suggests limited lipophilicity, favoring aqueous-based formulations.
- Stability data are not specified, so standard handling for alpha amino acid amide derivatives should be applied.
Regulatory status
Pirlimycin is a type of Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
